Accordingly, this study aimed to investigate the potential association between NAT2 promoter methylation clinical parameters indicating ATDILI and to assess whether NAT2 promoter methylation could serve as a specific biomarker of ATDILI in tuberculosis patients. Here, NAT2 is linked to tuberculosis.